Gilead Plan Kept Hepatitis C Drug Prices High, Senators Say
- Senators Wyden, Grassley release report on revenue strategy
- Harvoni, Sovaldi posted $13.3 billion in U.S. sales last year
This article is for subscribers only.
Gilead Sciences Inc., whose hepatitis C drugs Harvoni and Sovaldi had U.S. sales of $13.3 billion in the last year, pursued high list prices for the drugs instead of trying to make the treatments widely available, two U.S. senators said in a report Tuesday.
The company set the price of its first drug, Sovaldi, at $84,000 for a 12-week course partly in order to be able to charge a higher price later for Harvoni, its follow-up medicine that came to market the next year with a list price of $94,500, the lawmakers said.